SCHEMBL7123672

SCHEMBL7123672

OCc1cccc(-c2cc3nccc(Cl)c3s2)n1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 4/20 0.41
SRC P12931 1/20 0.35
TYK2 P29597 5/20 0.34
MAP3K8 P41279 2/20 0.33
STK17B O94768 1/20 0.33
CBFB Q13951 1/20 0.33
JAK2 O60674 2/20 0.32
JAK1 P23458 1/20 0.32
HSD17B1 P14061 2/20 0.32
HSD17B2 P37059 2/20 0.32
PSMB8 P28062 1/20 0.31
TRPV3 Q8NET8 1/20 0.31
S1PR4 O95977 1/20 0.31
KDM4E B2RXH2 1/20 0.30
LMNA P02545 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5241092 0.84 MCHR1 (0.43) MCHR1SRC
SCHEMBL7123648 0.80 GRM5 (0.41) MCHR1RAB9A
SCHEMBL7125950 0.78 MCHR1 (0.35) MCHR1SRCTYK2MAP3K8STK17B
SCHEMBL5241669 0.77 NUDT1 (0.41) MCHR1SRCTYK2JAK2JAK1
SCHEMBL5242363 0.77 NPC1 (0.42) MCHR1SRCMAP3K8KDM4ERAB9A
SCHEMBL5241630 0.77 MCHR1 (0.36) MCHR1TYK2MAP3K8STK17BJAK2
SCHEMBL5243357 0.76 KDM4E (0.50) MCHR1KDM4ELMNARAB9ASMN1; SMN2
SCHEMBL7118397 0.75 ALDH1A1 (0.43) TYK2JAK2KDM4ERAB9ASMN1; SMN2
SCHEMBL2602353 0.74 MST1R (0.35) MCHR1SRCMAP3K8
SCHEMBL6002954 0.73 IKBKB (0.54) MCHR1SRCMAP3K8STK17BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US disclosed
US-6492383-B1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2002-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents TYMP, DPYD, HPRT1 MCHR1 3278/4885SRC 3969/4885TYK2 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.